Thrivent Financial for Lutherans Sells 310,108 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Thrivent Financial for Lutherans lowered its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 56.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 235,057 shares of the company’s stock after selling 310,108 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Elanco Animal Health were worth $2,846,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new position in shares of Elanco Animal Health in the third quarter valued at $35,000. Jones Financial Companies Lllp lifted its position in Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after acquiring an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. boosted its stake in Elanco Animal Health by 221.2% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock valued at $60,000 after purchasing an additional 3,411 shares during the last quarter. Blue Trust Inc. increased its holdings in Elanco Animal Health by 47.7% during the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock worth $71,000 after purchasing an additional 1,894 shares in the last quarter. Finally, Spire Wealth Management raised its stake in shares of Elanco Animal Health by 107.4% in the fourth quarter. Spire Wealth Management now owns 7,776 shares of the company’s stock worth $94,000 after purchasing an additional 4,026 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were acquired at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the purchase, the director now owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. The trade was a 9.86 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.57% of the stock is owned by corporate insiders.

Elanco Animal Health Price Performance

ELAN opened at $10.81 on Friday. Elanco Animal Health Incorporated has a fifty-two week low of $10.03 and a fifty-two week high of $18.80. The firm has a 50-day moving average of $11.27 and a 200 day moving average of $12.48. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The firm has a market cap of $5.34 billion, a P/E ratio of 27.01, a PEG ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the previous year, the firm earned $0.08 earnings per share. The firm’s revenue was down 1.4% compared to the same quarter last year. On average, research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ELAN. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Stifel Nicolaus cut their price objective on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Morgan Stanley lowered their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. UBS Group cut their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Finally, Barclays decreased their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $15.17.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.